title: Combined IV and intra-arterial thrombolysis for acute ischemic stroke.
abstract: Combined IV and intra-arterial (IA) thrombolysis for acute ischemic stroke may offer advantages over either technique alone. Sixty-two nonrandomized patients with NIH Stroke Scale scores of > or =10 who met standard criteria for IV thrombolysis were treated with an IV/IA approach. Three-month modified Rankin Scale scores were 0 to 2 for 50% of patients, mortality was 18%, and symptomatic intracerebral hemorrhage occurred in 8%. IV/IA thrombolysis appeared safe and effective in this group.
authors.affiliation: Department of Neurology, University of Cincinnati Medical Center, 231 Albert Sabin Way, MSB Rm. 5161B, Cincinnati, OH, 45267-0525, USA. matthew.flaherty@uc.edu
authors.forename: M L
authors.initials: ML
authors.lastname: Flaherty
authors.forename: D
authors.initials: D
authors.lastname: Woo
authors.forename: B
authors.initials: B
authors.lastname: Kissela
authors.forename: E
authors.initials: E
authors.lastname: Jauch
authors.forename: A
authors.initials: A
authors.lastname: Pancioli
authors.forename: J
authors.initials: J
authors.lastname: Carrozzella
authors.forename: J
authors.initials: J
authors.lastname: Spilker
authors.forename: P
authors.initials: P
authors.lastname: Sekar
authors.forename: J
authors.initials: J
authors.lastname: Broderick
authors.forename: T
authors.initials: T
authors.lastname: Tomsick
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy*; D002533:Cerebral Angiography; D002543:Cerebral Hemorrhage / Q000139:chemically induced; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D007269:Injections, Intra-Arterial; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010960:Plasminogen Activators